Corbus Financial Statements From 2010 to 2024

CRBP Stock  USD 17.47  0.74  4.42%   
Corbus Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Corbus Pharmaceuticals Holding investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Corbus Pharmaceuticals financial statements helps investors assess Corbus Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Corbus Pharmaceuticals' valuation are summarized below:
Gross Profit
-16.1 M
Market Capitalization
212.8 M
Enterprise Value Revenue
8.2564
Earnings Share
(4.71)
Quarterly Revenue Growth
(1.00)
There are currently one hundred twenty fundamental signals for Corbus Pharmaceuticals Holding that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate Corbus Pharmaceuticals' prevailing fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction. As of 11/25/2024, Market Cap is likely to drop to about 15.2 M. In addition to that, Enterprise Value is likely to drop to about 18.8 M

Corbus Pharmaceuticals Total Revenue

881,705

Check Corbus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corbus Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 651.3 K, Interest Expense of 3.1 M or Selling General Administrative of 13.9 M, as well as many indicators such as Price To Sales Ratio of 93.82, Dividend Yield of 0.0 or Days Sales Outstanding of 191. Corbus financial statements analysis is a perfect complement when working with Corbus Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Corbus Pharmaceuticals Correlation against competitors.

Corbus Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding2.9 M4.3 M3.3 M
Pretty Stable
Total Assets50.5 M28.3 M37.1 M
Slightly volatile
Short and Long Term Debt Total11.1 M20.9 M8.3 M
Slightly volatile
Other Current LiabilitiesM11.1 M6.6 M
Slightly volatile
Total Current Liabilities16.9 M31.9 M12.5 M
Slightly volatile
Current Deferred Revenue1.091.154.2 M
Slightly volatile
Accounts PayableM3.2 MM
Slightly volatile
Cash13.2 M13.9 M21.7 M
Slightly volatile
Cash And Short Term Investments19.9 M20.9 M30.3 M
Slightly volatile
Common Stock Total Equity11.9 K11.4 K5.6 K
Slightly volatile
Liabilities And Stockholders Equity50.5 M28.3 M37.1 M
Slightly volatile
Non Current Liabilities Total3.1 M3.3 MM
Slightly volatile
Other Current Assets2.4 M2.6 M1.7 M
Slightly volatile
Other Stockholder Equity216.4 M429.8 M158.7 M
Slightly volatile
Total Liabilities25.1 M35.2 M18.9 M
Slightly volatile
Total Current Assets46.1 M23.5 M33.9 M
Slightly volatile
Short Term Debt18.5 M17.6 M3.5 M
Slightly volatile
Common Stock4204423.7 K
Slightly volatile
Other Liabilities24.3 K25.5 K190.2 K
Very volatile
Net Tangible Assets32.1 M37.9 M23.7 M
Slightly volatile
Property Plant And Equipment Net4.6 MM3.1 M
Slightly volatile
Non Current Assets Total4.9 M4.7 M3.3 M
Slightly volatile
Non Currrent Assets Other724.7 K690.2 K145 K
Slightly volatile
Net Receivables2.2 MMM
Slightly volatile
Capital Surpluse421.9 M401.8 M163.9 M
Slightly volatile
Property Plant And Equipment GrossM7.6 M3.3 M
Slightly volatile
Short and Long Term Debt17 M16.2 M2.9 M
Slightly volatile
Property Plant Equipment3.9 M6.3 M2.8 M
Slightly volatile
Capital Lease Obligations5.4 M4.7 M3.2 M
Slightly volatile
Non Current Liabilities Other42.2 K44.4 K1.6 M
Pretty Stable
Net Invested Capital8.8 M9.3 M48.2 M
Slightly volatile
Capital Stock4204425.4 K
Pretty Stable
Long Term Debt Total14.4 M16.2 M17.7 M
Slightly volatile

Corbus Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization651.3 K640.6 K477.8 K
Slightly volatile
Selling General Administrative13.9 M13.9 M10.3 M
Slightly volatile
Other Operating Expenses50.8 M45.1 M37.4 M
Slightly volatile
Research Development36.9 M31.2 M27.1 M
Slightly volatile
Total Operating Expenses13.2 M13.9 M32.8 M
Slightly volatile
Cost Of Revenue32.7 M31.2 M11.3 M
Slightly volatile
Interest Income1.5 M1.4 M599.3 K
Slightly volatile
Reconciled Depreciation1.3 M1.4 M752.1 K
Slightly volatile
Selling And Marketing Expenses11.1 B12.5 B13.6 B
Slightly volatile

Corbus Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation6.1 M3.5 M4.5 M
Slightly volatile
Begin Period Cash Flow30 M17.2 M22.1 M
Slightly volatile
End Period Cash Flow13.2 M13.9 M21.9 M
Slightly volatile
Sale Purchase Of Stock171.7 M163.5 M64.9 M
Slightly volatile
Depreciation834.2 K640.6 K563.9 K
Slightly volatile
Change To Netincome7.3 M7.6 MM
Slightly volatile
Issuance Of Capital Stock231.9 K244.1 K23.6 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio93.8298.8284.9676
Very volatile
Days Sales Outstanding191275203
Pretty Stable
Invested Capital215241263
Slightly volatile
Average Payables2.5 M2.4 M1.7 M
Slightly volatile
Stock Based Compensation To Revenue10.169.684.072
Slightly volatile
Capex To Depreciation0.00990.01043.173
Slightly volatile
EV To Sales82.1610173.2377
Very volatile
Payables Turnover10.39.80574.3297
Pretty Stable
Sales General And Administrative To Revenue21.8920.859.3425
Slightly volatile
Research And Ddevelopement To Revenue39.0637.217.9792
Slightly volatile
Capex To Revenue0.06710.07070.1644
Slightly volatile
Cash Per Share4.634.87612.9344
Slightly volatile
Days Payables Outstanding35.3637.2231K
Pretty Stable
Income Quality0.620.80940.7767
Very volatile
Current Ratio0.70.73833.1459
Very volatile
Receivables Turnover1.311.373.8508
Pretty Stable
Graham Number18.2819.23846.1556
Slightly volatile
Capex Per Share0.00280.00290.265
Very volatile
Average Receivables792 K1.2 M921.5 K
Slightly volatile
Revenue Per Share0.180.191.893
Very volatile
Interest Debt Per Share4.644.42172.3767
Slightly volatile
Debt To Assets0.390.57330.4241
Slightly volatile
Days Of Payables Outstanding35.3637.2231K
Pretty Stable
Ebt Per Ebit1.080.98951.0018
Slightly volatile
Quick Ratio0.70.73833.1503
Very volatile
Net Income Per E B T0.861.191.003
Slightly volatile
Cash Ratio0.410.43632.4731
Pretty Stable
Days Of Sales Outstanding191275203
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.131.151.0424
Slightly volatile
Fixed Asset Turnover0.140.12592.899
Slightly volatile
Debt Ratio0.390.57330.4241
Slightly volatile
Price Sales Ratio93.8298.8284.9676
Very volatile
Asset Turnover0.0070.00740.0902
Very volatile

Corbus Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap15.2 M16 M145.2 M
Very volatile
Working Capital215241263
Slightly volatile
Enterprise Value18.8 M19.8 M121.1 M
Very volatile

Corbus Fundamental Market Drivers

Cash And Short Term Investments20.9 M

Corbus Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Corbus Pharmaceuticals Financial Statements

Corbus Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Corbus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Corbus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Corbus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue 1.15  1.09 
Cost Of Revenue31.2 M32.7 M
Stock Based Compensation To Revenue 9.68  10.16 
Sales General And Administrative To Revenue 20.85  21.89 
Research And Ddevelopement To Revenue 37.20  39.06 
Capex To Revenue 0.07  0.07 
Revenue Per Share 0.19  0.18 
Ebit Per Revenue(73.03)(69.37)

Pair Trading with Corbus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corbus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Corbus Stock

  0.83VALN Valneva SE ADRPairCorr
  0.61JNJ Johnson Johnson Sell-off TrendPairCorr

Moving against Corbus Stock

  0.7KZR Kezar Life SciencesPairCorr
  0.59MLYS Mineralys Therapeutics,PairCorr
The ability to find closely correlated positions to Corbus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corbus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corbus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corbus Pharmaceuticals Holding to buy it.
The correlation of Corbus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corbus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corbus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corbus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Corbus Stock Analysis

When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.